182352-48-3

Basic information

• Product Name: 2,5-Dihydro-4-hydroxy-2-oxo-1H-pyrrole-1-carboxylic acid 1,1-dimethylethyl ester
• Synonyms: 2,5-Dihydro-4-hydroxy-2-oxo-1H-pyrrole-1-carboxylic acid 1,1-dimethylethyl ester;1-Boc-4-hydroxy-2-oxo-2,5-dihydro-pyrrol, 98%;tert-butyl 4-hydroxy-2-oxo-2H-pyrrole-1(5H)-carboxylate
• CAS NO: 182352-48-3
• Molecular Formula: C₉H₁₃NO₄
• Molecular Weight: 199.20382
• Mol File: 182352-48-3.mol
• Article Data: 12

Chemical Properties

• Melting Point: 123-127℃
• Boiling Point: 279℃
• Flash Point: 122℃
• Appearance: /
• Density: 1.313g/cm³
• Vapor Pressure: 0.001mmHg at 25°C
• Refractive Index: 1.547
• PKA: 4.50±1.00(Predicted)
• CAS DataBase Reference: 2,5-Dihydro-4-hydroxy-2-oxo-1H-pyrrole-1-carboxylic acid 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 2,5-Dihydro-4-hydroxy-2-oxo-1H-pyrrole-1-carboxylic acid 1,1-dimethylethyl ester(182352-48-3)
• EPA Substance Registry System: 2,5-Dihydro-4-hydroxy-2-oxo-1H-pyrrole-1-carboxylic acid 1,1-dimethylethyl ester(182352-48-3)

Safety Data

• Hazardous Substances Data: 182352-48-3(Hazardous Substances Data)

Usage

Description

2,5-Dihydro-4-hydroxy-2-oxo-1H-pyrrole-1-carboxylic acid 1,1-dimethylethyl ester is a chemical compound with the molecular formula C9H13NO4. It is a derivative of pyrrole carboxylic acid and is commonly used as a biochemical tool in research laboratories.

Uses

Used in Pharmaceutical Research:
2,5-Dihydro-4-hydroxy-2-oxo-1H-pyrrole-1-carboxylic acid 1,1-dimethylethyl ester is used as a biochemical tool for research purposes in the field of pharmaceuticals. Its unique properties make it of interest in the development of new drug compounds.
Used in Organic Synthesis:
2,5-Dihydro-4-hydroxy-2-oxo-1H-pyrrole-1-carboxylic acid 1,1-dimethylethyl ester is used as a key intermediate in the synthesis of various organic compounds, contributing to the advancement of chemical research and development.
Used in Disease Treatment:
Although not explicitly stated in the provided materials, the compound's potential applications in the treatment of certain diseases suggest that it could be used as a therapeutic agent in the medical field, pending further research and development.

InChI:InChI=1/C9H13NO4/c1-9(2,3)14-8(13)10-5-6(11)4-7(10)12/h4,11H,5H2,1-3H3

Upstream product

• 4530-20-5 BOC-glycine 
• 2033-24-1 cycl-isopropylidene malonate 
• 108-23-6 isopropyl chloroformate 
• 182352-25-6 5-(N-tert-butoxycarbonyglycyl)meldrum’s acid 

Downstream Products

• 1161439-78-6 1-(tert-butoxycarbonyl)-4-hydroxy-3-(4′-methoxyphenyl)-1H-pyrrol-2(5H)-one 
• 928215-97-8 4-(4-chlorophenyl)-2-oxo-2,5-dihydropyrrole-1-carboxylic acid tert-butyl ester 
• 928215-95-6 tert-butyl 2,5-dihydro-4-(4'-methoxyphenyl)-2-oxo-1H-pyrrole-1-carboxylate 
• 928215-96-7 2-oxo-4-phenyl-2,5-dihydropyrrole-1-carboxylic acid tert-butyl ester 
• 443680-33-9 2-oxo-4-(toluene-4-sulfonyloxy)-2,5-dihydropyrrole-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

Efficient total synthesis of pulchellalactam, a CD45 protein tyrosine phosphatase inhibitor

A new approach to a CD45 protein tyrosine phosphatase inhibitor, pulchellalactam, is described. The key step of the sequence involves addition and elimination of an enolic lactam in a single step and 70% yield, employing an organocuprate reagent. The resulting α,β-unsaturated lactam could be condensed with isobutyraldehyde to produce Z-pulchellalactam or converted into siloxypyrrole, which was subjected to the BF3·Et2O-promoted coupling reaction with isobutyraldehyde to afford E-pulchellalactam after E1-cB elimination and TFA deprotection. This first total synthesis afforded Z-pulchellalactam in six steps and 32% overall yield from Boc-glycine. The same sequence of reactions could also be applied to the liquid- or solid-phase synthesis of trifunctionalized pulchellalactam derivatives.

COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS

Provided are methods for treating neurological disorders using compounds of Formula (I), and pharmaceutically acceptable salts and compositions thereof.

P300/CBP HAT INHIBITORS

Provided are compounds of Formula (I): and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with histone acetyltransferase (HAT).

Aminoheteroaryl benzamides as kinase inhibitors

The present invention provides a compound of Formula (I) or a salt thereof; and therapeutic uses of these compounds. The present invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds with a therapeutic co-agent.